- Home
- Publications
- Publication Search
- Publication Details
Title
The evolving genomic classification of lung cancer
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 232, Issue 2, Pages 121-133
Publisher
Wiley
Online
2013-10-12
DOI
10.1002/path.4275
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Impact of Genomic Changes on Treatment of Lung Cancer
- (2013) Stephanie Cardarella et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients
- (2013) H. Tang et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
- (2013) Christina Brzezniak et al. EXPERT OPINION ON PHARMACOTHERAPY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
- (2013) William D. Travis et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
- (2013) Tianhong Li et al. JOURNAL OF CLINICAL ONCOLOGY
- New Targetable Oncogenes in Non–Small-Cell Lung Cancer
- (2013) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations
- (2013) Sanja Dacic JOURNAL OF CLINICAL PATHOLOGY
- Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
- (2013) Ka-Fai To et al. Journal of Thoracic Oncology
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
- (2013) Vamsidhar Velcheti et al. Journal of Thoracic Oncology
- Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib
- (2013) M. Bos et al. LUNG CANCER
- Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer
- (2013) Thang N. Tran et al. LUNG CANCER
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
- (2013) M. F. Burbridge et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
- (2012) A. Thomas et al. ANNALS OF ONCOLOGY
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups
- (2012) F. Andre et al. CLINICAL CANCER RESEARCH
- Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
- (2012) V. M. Rimkunas et al. CLINICAL CANCER RESEARCH
- Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
- (2012) J. Zhang et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
- (2012) David R. Spigel et al. Clinical Lung Cancer
- Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
- (2012) Hiromasa Takeda et al. EXPERIMENTAL CELL RESEARCH
- Translating genomic information into clinical medicine: Lung cancer as a paradigm
- (2012) M. A. Levy et al. GENOME RESEARCH
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
- (2012) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies
- (2012) Johannes R Kratz et al. LANCET
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel
- (2012) Rajesh Patel et al. PLoS One
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
- (2011) Zengliu Su et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
- (2011) J. E. Chaft et al. MOLECULAR CANCER THERAPEUTICS
- Methodological and practical challenges for personalized cancer therapies
- (2011) Ignacio I. Wistuba et al. Nature Reviews Clinical Oncology
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Clinical implications ofMETgene copy number in lung cancer
- (2010) Luca Toschi et al. Future Oncology
- Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer
- (2010) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic medicine in non-small cell lung cancer: Paving the path to personalized care
- (2010) Krishna Bajee SRIRAM et al. RESPIROLOGY
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
- (2008) A. J. Gonzales et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now